MT-I
Melanocortin Receptor Agonist
DoseGear research brief
Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.
Subcutaneous injection delivers peptide directly into systemic circulation. Selectively activates MC1R receptors to stimulate melanin production. Short half-life of approximately 30 minutes necessitates multiple daily dosing for sustained effect.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Synthetic alpha-MSH analog associated with afamelanotide development.
Pigmentation and photoprotection research through melanocortin-1-receptor stimulation and melanogenesis.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Loading phase | 0.25-0.5mg | 1-2x daily for 1-2 weeks | Subcutaneous |
| Maintenance | 0.25-0.5mg | 2-3x weekly | Subcutaneous |
Reference cycle
2-4 week loading phase, then ongoing maintenance as needed
Reference storage
Refrigerate reconstituted solution at 2-8°C, use within 4 weeks
No profile entries reported.
MT-I Photoprotection Study
Melanocortin Receptor Binding Study
Pharmacokinetics Injectable MT-I
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
